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Abstract
We evaluated the cytotoxic effects of four prostaglandin analogs (PGAs) used to treat glau-
coma. First we established primary cultures of conjunctival stromal cells from healthy do-
nors. Then cell cultures were incubated with different concentrations (0, 0.1, 1, 5, 25, 50 and
100%) of commercial formulations of bimatoprost, tafluprost, travoprost and latanoprost for
increasing periods (5 and 30 min, 1 h, 6 h and 24 h) and cell survival was assessed with
three different methods: WST-1, MTT and calcein/AM-ethidium homodimer-1 assays. Our
results showed that all PGAs were associated with a certain level of cell damage, which cor-
related significantly with the concentration of PGA used, and to a lesser extent with culture
time. Tafluprost tended to be less toxic than bimatoprost, travoprost and latanoprost after all
culture periods. The results for WST-1, MTT and calcein/AM-ethidium homodimer-1 corre-
lated closely. When the average lethal dose 50 was calculated, we found that the most cyto-
toxic drug was latanoprost, whereas tafluprost was the most sparing of the ocular surface in
vitro. These results indicate the need to design novel PGAs with high effectiveness but free
from the cytotoxic effects that we found, or at least to obtain drugs that are functional at low
dosages. The fact that the commercial formulation of tafluprost used in this work was pre-
servative-free may support the current tendency to eliminate preservatives from eye drops
for clinical use.
Introduction
Glaucoma is the second most frequent cause of blindness worldwide, with over 11 million
cases attributed to this disease [1,2]. Progression can be slowed by reducing intraocular pres-
sure (IOP) pharmacologically [3,4]. Some of the most popular and efficient drugs for the treat-
ment of glaucoma are prostaglandin analogs (PGAs). These drugs are currently considered the
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first line of treatment for glaucoma because of their efficacy and safety [5]. PGAs act primarily
by enhancing uveoscleral outflow of the aqueous humor, and thereby decreasing IOP [6–8].
Four different PGAs are currently available in Europe for clinical use: travoprost, latanoprost,
bimatoprost and tafluprost. However, the effect of these drugs on human cells are not
well known.
In most cases chronic treatment with one or several drugs is necessary for the efficient con-
trol of IOP. Although most treatments are free from severe systemic effects, the chronic use of
these drugs may be associated with local side effects in the long term. In this regard, several
studies reported that the use of PGAs may lead to conjunctival hyperemia [9–11], increased
iris pigmentation [12–14], changes in the biomechanical properties of the cornea [15], eye sur-
face inflammation, dry eye syndrome and failure of filtration surgery [16–18]. However, the di-
rect cytotoxic effects of PGAs for clinical use have not been fully established.
A number of studies have determined the cytotoxic effects of several PGAs and other oph-
thalmic agents. Most of these studies were done with animal cells [19,20] or immortalized
human cell lines [21–24], and very few studies used normal human cells isolated from the con-
junctiva [25,26]. In addition, very few studies have compared all four PGAs currently available
in Europe [27]. Therefore, we lack sufficient knowledge about how the various PGAs may affect
the ocular surface.
In this study we evaluated the cytotoxic effects of four PGAs on normal human conjunctival
cell cultures at different concentrations and times, using three methods to determine the bio-
safety levels of the drugs used most commonly to control IOP.
Materials and Methods
Conjunctival stromal cell cultures
Primary cultures of human conjunctival stromal cells were established from small surgical bi-
opsies obtained from 3 healthy donors undergoing eye surgery (i.e. strabismus or retinal de-
tachment surgery) who had not been previously treated with eye drops. Average age of the
donors was 50 years. Cells were isolated from tissue biopsies using a 2% (w/v) solution of type I
collagenase from Clostridium hystoliticum (Gibco BRL Life Technologies Ref. 17100–017,
Karlsruhe, Germany), corresponding to approximately 100 U/ml. Briefly, biopsies were incu-
bated in the collagenase solution at 37C for 4–6 h until complete dissociation with slight agita-
tion. Detached cells were then harvested by centrifugation, supernatant was discarded and the
cell pellet was resuspended in DMEM with 10% fetal calf serum as culture medium (Sigma-Al-
drich ref. D5796, Saint-Quentin-Fallavier, France) and transferred to culture flasks. Cells were
cultivated at 37C in a 5% CO2 atmosphere using the same culture medium, and subconfluent
cells were subcultured to new culture flasks using trypsin-EDTA solution (Sigma-Aldrich ref.
T3924) until passage 6. All experiments were carried out on subconfluent cells corresponding
to cell passages 3 to 6. All donors gave their written consent to participate in the study, and this
study was approved by the San Cecilio University Hospital research and ethics committee.
Study groups
Commercially available formulations of the four PGAs that are currently approved for clinical
use were assayed in this work: 0.03% bimatoprost with 0.005% benzalkonium chloride (BAK)
(Lumigan, Allergan, Irvine, CA), 0.005% latanoprost with 0.02% BAK (Xalatan, Pfizer, New
York, NY); 0.0015% tafluprost without preservatives (Saflutan, Merck, Kenilworth, NJ), and
0.015% travoprost with 0.04% BAK (Travatan, Alcon Laboratories, Fort Worth, TX). For each
product we studied 6 different concentrations of the commercial formulation diluted in culture
medium: 100%, 50%, 25%, 5%, 1% and 0.1%. As a negative control for cytotoxicity, cells were
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incubated in DMEM culture medium, and as a positive control, 1% Triton-X100 was used. In
all cases, 10,000 cells were subcultured in each well of a 96-well plate. Once the cells attached to
the culture surface 24 h later, the culture medium was removed and 100 μL of each PGA dilu-
tion was added to each well. Therefore, 0.01 μl of each dilution were used per cultured cell.
Then all cell viability assays were carried out after 5 different incubation times: 5 and 30 min
and 1, 6 and 24 h. All experiments were done in triplicate (3 different cell cultures from 3
donors).
Determination of cell viability and functional status with WST-1 assays
Cell viability and functional status were determined with the Water-Soluble Tetrazolium Salt-1
(WST-1) colorimetric assay on conjunctival cells incubated on different PGA dilutions for dif-
ferent times (Cell Proliferation Reagent WST-1, Roche Diagnostics, Indianapolis, IN). WST-1
is a tetrazolium dye containing an electron coupling reagent that is cleaved by the mitochondri-
al dehydrogenase enzyme to a formazan dye. Therefore, the amount of formazan dye formed
correlates directly with the number of metabolically active cells in the culture. For this analysis,
each well containing the cells was washed twice in PBS, and then 100 μL of DMEM and 10 μL
of the cell proliferation reagent WST-1 were added to each well. This mixture was incubated
for 4 h at 37°C in a cell culture incubator. Then the plates were agitated for 1 min and absor-
bance at 450 nm was quantified in a spectrophotometer.
Determination of cell viability and functional status with MTT assays
To determine cell viability and function with MTT, each well was washed twice in PBS. Then
100 μL DMEM and 10 μL MTT labeling agent were added to each well. This mixture was incu-
bated for 4 h at 37°C in a cell culture incubator. Then 100 μL solubilization solution was added
per well and the plates were incubated overnight to allow formazan crystals to solubilize. Final-
ly, absorbance was quantified at 550 nm in a spectrophotometer. This colorimetric nonradioac-
tive assay is based on the metabolic bromide reduction of 3-(4,5-dimethylthiazol-2-yl)-
2,5-diphenyl tetrazol (MTT) by functional cells, and is used to determine mitochondrial
cell function.
Determination of cell viability and functional status with a dual
cytoplasmic and nuclear calcein/AM-ethidium homodimer-1 assay
(LIVE/DEAD)
To simultaneously analyze cell function based on cytoplasmic metabolism and cell viability
based on cell membrane integrity, we used the calcein/AM-ethidium homodimer-1 Viability/
Cytotoxicity assay kit (LIVE/DEAD, Life Technologies, Carlsbad, CA). For this assay, 20,000
cells were cultured on chamber slides (Lab-Tek Chamber Slides, Nunc, Roskilde, Denmark)
and allowed to attach to the slides for 24 h. Then the culture medium was removed and 500 μL
of each PGA dilution was added to each chamber. After incubation times of 5 and 30 min, 1, 6
and 24 h, the supernatant was removed and the cells were washed twice with PBS and stained
with the LIVE/DEAD assay reagents (calcein/AM and ethidium homodimer-1) (Invitrogen,
Carlsbad, CA) according to protocols supplied by Invitrogen. Finally, the number of live
(green) and dead (red) cells was determined with a fluorescence microscope, and the percent-
age of live and dead cells was calculated for each study group. For each culture condition, three
determinations were done.
Prostaglandins and Eye Surface Cells
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Statistical analysis
First the dose of each PGA able to reduce cell viability or cell function by 50% was calculated
for each compound and each culture period, and an average value was obtained for each PGA
(average lethal dose 50, LD50).
Pair-wise comparisons between two study groups (two different PGAs for each incubation
time) were done with the Wilcoxon nonparametric test to evaluate the statistical significance of
differences between groups. The Kendall tau correlation test was used to establish correlations
between variables (times, concentrations and cell viability as determined by the different
methods).
A p value of 0.05 was considered statistically significant, and all tests were two-tailed. The
SPSS v. 16.00 application was used for all statistical analysis.
Results
Cytotoxic effects of PGAs determined by WST-1 assays
Our analysis of cytotoxic cell damage induced by the four PGAs showed that all eye drop for-
mulations had some degree of cytotoxicity. When we compared the metabolic activity of cells
incubated with the different drugs to negative controls without PGA using the WST-1 method,
we found a statistically significant decrease in cell activity and viability at all incubation times
(5 and 30 min, 1, 6 and 24 h) (Table 1 and Fig 1). However, comparisons with positive controls
showed that the cytotoxic effects of 0.03% bimatoprost and latanoprost did not differ from
those induced by Triton X-100, which was toxic to cells at all incubation times. Similarly, travo-
prost was highly toxic to conjunctival cells after incubation for 30 min to 24 h, but was
Table 1. Statistical p values (Wilcoxon nonparametric test) for comparisons of the results with theWST-1 assay.
WST-1 Bimatoprost Taﬂuprost Travoprost Latanoprost Positive control Negative control
5 min Bimatoprost - 0.120 0.604 0.000* 0.002* 0.033*
Taﬂuprost 0.120 - 0.002* 0.000* 0.006* 0.006*
Travoprost 0.604 0.002* - 0.000* 0.002* 0.004*
Latanoprost 0.000* 0.000* 0.000* - 0.002* 0.937
30 min Bimatoprost - 0.000* 0.460 0.000* 0.000* 0.219
Taﬂuprost 0.000* - 0.000* 0.037* 0.006* 0.000*
Travoprost 0.460 0.000* - 0.002* 0.000* 0.061
Latanoprost 0.000* 0.037* 0.002* - 0.000* 0.031*
1 h Bimatoprost - 0.683 0.074 0.003* 0.000* 0.535
Taﬂuprost 0.683 - 0.029* 0.000* 0.000* 0.000*
Travoprost 0.074 0.029* - 0.000* 0.000* 0.623
Latanoprost 0.003* 0.000* 0.000* - 0.000* 0.134
6 h Bimatoprost - 0.306 0.179 0.737 0.002* 0.002*
Taﬂuprost 0.306 - 0.001* 0.000* 0.002* 0.002*
Travoprost 0.179 0.001* - 0.900 0.002* 0.002*
Latanoprost 0.737 0.000* 0.900 - 0.002* 0.388
24 h Bimatoprost - 0.318 0.116 0.000* 0.000* 0.157
Taﬂuprost 0.318 - 0.012* 0.001* 0.000* 0.003*
Travoprost 0.116 0.012* - 0.000* 0.000* 0.016*
Latanoprost 0.000* 0.001* 0.000* - 0.000* 0.760
* Statistically signiﬁcant p values
doi:10.1371/journal.pone.0129419.t001
Prostaglandins and Eye Surface Cells
PLOS ONE | DOI:10.1371/journal.pone.0129419 June 12, 2015 4 / 12
significantly less toxic than the positive control at 5 min. In contrast, tafluprost was more toxic
that the control (drug-free) culture medium but significantly less cytotoxic than the control
Triton X-100. As shown in Table 2, statistical analysis revealed that the effect of all four PGAs
was different, although some similarities were found between specific drugs, especially latano-
prost and tafluprost. A statistically significant negative correlation was found between cell via-
bility as determined by WST-1 assays and incubation time (p = 0.001, r = −0.222), drug
concentration (p = 0.000, r = −0.470) and the specific PGA used (p = 0.028, r = −0.150). Inter-
estingly, our WST-1 results correlated positively with those obtained with the MTT assay
(p = 0.000, r = 0.551) and the LIVE/DEAD assay (p = 0.000, r = 0.512).
Calculation of the average LD50 showed that the most cytotoxic drug was latanoprost,
which decreased cell viability and metabolism to 50% of the control value at a concentration of
just 8.08% of the commercial product. In contrast, the least cytotoxic PGA was tafluprost,
which reduced cell activity and viability by 50% at an average concentration of 36.77%
(Table 2).
Cytotoxic effects of PGAs determined by MTT assays
The MTT assay showed that most PGAs reduced cell mitochondrial activity after all incubation
periods except for bimatoprost (at 5 and 60 min) and tafluprost (at 5 min and 24 h) (Table 3
and Fig 2). Comparisons of the cytotoxic effects of all four PGAs to the positive control for
mortality showed that treatment with bimatoprost, travoprost and latanoprost reduced cell
metabolic activity to levels similar to those of the Triton X-100 control at 30 and 60 min, 6 h
and 24 h, suggesting that these drugs were as cytotoxic as the control after these periods. How-
ever, cells treated with tafluprost for 5, 30 and 60 min, 6 h and 24 h and with bimatoprost and
latanoprost for 5 min showed significantly different MTT activity levels compared to the posi-
tive control. In addition, statistical comparisons of the four PGAs showed that tafluprost was
Fig 1. Average cell viability and functional status according to theWST-1 assay in conjunctival cells incubated with different PGA dilutions for
different times.NC: negative controls for cytotoxicity; PC: positive controls for cytotoxicity.
doi:10.1371/journal.pone.0129419.g001
Table 2. Average lethal dose 50 (LD50) for each prostaglandin analog and each assay.
WST-1 MTT LIVE/DEAD
Bimatoprost 16.98% 18.36% 32.56%
Taﬂuprost 36.77% 51.45% 77.06%
Travoprost 17.15% 14.52% 32.08%
Latanoprost 8.08% 8.52% 31.36%
doi:10.1371/journal.pone.0129419.t002
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significantly different from the other three PGAs after most incubation periods. A statistically
significant negative correlation was found between cell viability as determined by MTT assays
and PGA concentration (p = 0.000, r = −0.485), and between viability and the specific type of
PGA (p = 0.001, r = −0.219), but no such correlation was found between viability and incuba-
tion time. The results for the MTT assay correlated positively with those for the WST-1 assay
(p = 0.000, r = 0.551) and the LIVE/DEAD assay (p = 0.000, r = 0.353).
The average LD50 with the MTT method indicated that the most cytotoxic drug was latano-
prost, which decreased cell viability and metabolism to 50% of the control value at a concentra-
tion of 8.52% of the commercial product. The least cytotoxic PGA was tafluprost, which reduced
cell activity and viability by 50% at an average concentration of 51.45% (Table 2).
Table 3. Statistical p values (Wilcoxon nonparametric test) for comparisons of the results with the MTT assay.
MTT Bimatoprost Taﬂuprost Travoprost Latanoprost Positive control Negative control
5 min Bimatoprost - 0.000* 0.573 0.209 0.065 0.003*
Taﬂuprost 0.000* - 0.000* 0.000* 0.117 0.003*
Travoprost 0.573 0.000* - 0.322 0.002* 0.013*
Latanoprost 0.209 0.000* 0.322 - 0.003* 0.003*
30 min Bimatoprost - 0.003* 0.068 0.001* 0.592 0.002*
Taﬂuprost 0.003* - 0.000* 0.000* 0.002* 0.002*
Travoprost 0.068 0.000* - 0.001* 0.637 0.002*
Latanoprost 0.000* 0.000* 0.001* - 0.454 0.002*
1 h Bimatoprost - 0.000* 0.931 0.068 0.001* 0.002*
Taﬂuprost 0.000* - 0.000* 0.008* 0.180 0.000*
Travoprost 0.931 0.000* - 0.198 0.002* 0.003*
Latanoprost 0.068 0.008* 0.198 - 0.000* 0.486
6 h Bimatoprost - 0.000* 0.001* 0.122 0.001* 0.001*
Taﬂuprost 0.000* - 0.000* 0.000* 0.975 0.005*
Travoprost 0.001* 0.000* - 0.033* 0.001* 0.001*
Latanoprost 0.122 0.000* 0.033* - 0.001* 0.002*
24 h Bimatoprost - 0.206 0.116 0.000* 0.000* 0.157
Taﬂuprost 0.206 - 0.011* 0.000* 0.011* 0.003*
Travoprost 0.116 0.011* - 0.000* 0.000* 0.016*
Latanoprost 0.000* 0.000* 0.000* - 0.000* 0.760
* Statistically signiﬁcant p values
doi:10.1371/journal.pone.0129419.t003
Fig 2. Average cell viability and functional status according to the MTT assay in conjunctival cells incubated with different PGA dilutions for
different times.NC: negative controls for cytotoxicity; PC: positive controls for cytotoxicity.
doi:10.1371/journal.pone.0129419.g002
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Cytotoxic effects of PGAs determined by LIVE/DEAD assays
When we analyzed cell viability with the dual cytoplasmic and nuclear cell viability and cell
function assay LIVE/DEAD, we found that the results for the PGAs differed significantly from
the positive and negative controls, suggesting that all PGAs altered cell viability, albeit to a less-
er extent than the Triton X-100 control after all periods (Table 4 and Figs 3 and 4). Our com-
parison of the cytotoxic effects of the four PGAs showed that tafluprost tended to result in the
highest levels of cell viability and function, especially at the highest doses, although the differ-
ences between incubation periods were not statistically significant. Statistically significant
Table 4. Statistical p values (Wilcoxon nonparametric test) for comparisons of the results with the LIVE/DEAD assay.
LIVE/DEAD Bimatoprost Taﬂuprost Travoprost Latanoprost Positive control Negative control
5 min Bimatoprost - 0.002* 0.028* 0.005* 0.002* 0.002*
Taﬂuprost 0.002* — 0.028* 0.099 0.002* 0.002*
Travoprost 0.028* 0.028* - 0.875 0.002* 0.002*
Latanoprost 0.005* 0.099 0.875 - 0.002* 0.002*
30 min Bimatoprost - 0.099 0.331 0.035* 0.002* 0.026*
Taﬂuprost 0.099 - 0.049* 0.271 0.002* 0.002*
Travoprost 0.331 0.049* - 0.331 0.002* 0.005*
Latanoprost 0.035* 0.271 0.331 - 0.005* 0.011*
1 h Bimatoprost - 0.028* 0.011* 0.506 0.002* 0.011*
Taﬂuprost 0.028* - 0.012* 0.049* 0.002* 0.002*
Travoprost 0.011* 0.012* - 0.878 0.002* 0.011*
Latanoprost 0.506 0.049* 0.878 - 0.002* 0.005*
6 h Bimatoprost - 0.099 0.574 0.074 0.002* 0.005*
Taﬂuprost 0.099 - 0.157 0.023* 0.002* 0.002*
Travoprost 0.574 0.157 - 0.011* 0.005* 0.011*
Latanoprost 0.074 0.023* 0.011* - 0.002* 0.026*
24 h Bimatoprost - 0.574 0.026* 0.113 0.002* 0.026*
Taﬂuprost 0.574 - 0.021* 0.012* 0.002* 0.005*
Travoprost 0.026* 0.021* - 0.916 0.002* 0.026*
Latanoprost 0.113 0.012* 0.916 - 0.002* 0.026*
* Statistically signiﬁcant p values
doi:10.1371/journal.pone.0129419.t004
Fig 3. Average cell viability and functional status according to the LIVE/DEAD assay in conjunctival cells incubated with different PGA dilutions
for different times.NC: negative controls for cytotoxicity; PC: positive controls for cytotoxicity.
doi:10.1371/journal.pone.0129419.g003
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negative correlations were found between cell viability determined by LIVE/DEAD and incu-
bation time (p = 0.000, r = −0.366), and between viability and the concentration of PGA
(p = 0.000, r = −0.451), although no such correlation was found between viability and the type
of PGA used. These results correlated positively with those obtained with the WST-1 assay
(p = 0.000, r = 0.512) and the MTT assay (p = 0.000, r = 0.353).
The average LD50 for the LIVE/DEAD assay confirmed that the PGA formulation with the
weakest cytotoxic effect was tafluprost (a 77.06% concentration led to 50% cell death), whereas
the average LD50 for the rest of the cytotoxic agents ranged between 31.36% and 32.56%
(Table 2).
Discussion
Glaucoma is a chronic disease that often requires years or decades of medical treatment. For
this reason, the effects of drugs used on the ocular surface must be determined in normal
human cells and with an array of methods and techniques, and additional studies to compare
the four PGAs currently approved for clinical use are needed. Whereas most previous studies
used immortalized cell lines to study cell viability [22,28], we used primary cultures of human
conjunctival cells isolated from normal donors in material obtained during routine ophthalmic
surgical procedures. Normal cells represent a much more physiological system that yields re-
sults which can be more directly extrapolated to the clinical situation than those obtained with
immortalized cell lines, which usually have important genetic abnormalities [29].
Strikingly, our results revealed that all PGAs were cytotoxic to cultured conjunctival cells, al-
though we found significant differences among the four PGAs analyzed here. As expected, our
results showed that both the concentration and the incubation period had crucial effects on cell
viability, and cells incubated with high concentrations of PGA for longer periods showed the
greatest cell damage. Interestingly, the cytotoxic effect of concentration was more important
Fig 4. Illustrative images corresponding to the analysis of cell viability and functional status according to the LIVE/DEAD assay in conjunctival
cells incubated with different PGAs dilution for different times. A: negative controls for cytotoxicity; B: positive controls for cytotoxicity; C: cells incubated
with a 25% concentration of bimatoprost for 1 h; D: cells incubated with a 25% concentration of tafluprost for 1 h; E: cells incubated with a 25% concentration
of travoprost for 1 h; F: cells incubated with a 25% concentration of latanoprost for 1 h. Scale bars: 100 μm.
doi:10.1371/journal.pone.0129419.g004
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that incubation time, with a clearer negative correlation in all three methods used here. These
results are in agreement with previous reports suggesting that concentration had a greater ef-
fect than incubation time in several cell types incubated with different drugs [24,30]. Together,
the results indicate a need to design novel PGAs with high effectiveness but free from the cyto-
toxic effects that we found, or at least to obtain drugs that are functional at low dosages. Care
should be taken before extrapolating the results to in vivo situations, since the concentration of
each drug and the volume per cell used in the present work could be different to real in
vivo environment.
Regarding incubation time, several studies reported that the half-life of this type of eye drops
is very short [31,32]. We determined the cytotoxic effects of all four PGAs after short periods
(5 min, 30 min and 1 h) to reproduce the pharmacokinetics of these compounds. In addition, to
better characterize these PGAs, we also analyzed their effects after longer periods (6 h and 24 h).
Although these long incubation times may not reproduce the usual clinical situation, it is impor-
tant to determine the effects of these commonly used drugs after longer periods which mimic the
situation most patients face when they need to use these eye drops for long-term treatment.
In general, our results show that the PGA associated with the best cell viability was taflu-
prost. We note that this is the only one of the four compounds evaluated here that is preserva-
tive-free, whereas the other PGAs contain BAK in their formulation. To reproduce the clinical
situation more accurately, we always used commercially available products without separating
the active components from the preservatives. Our results should therefore be interpreted with
due caution. Ophthalmic eye drops commonly contain BAK, a preservative with established
cytotoxicity and side effects both in vivo and in vitro. It is considered a stimulating factor re-
sponsible for inflammation [33], and the long-term use of anti-glaucoma medication with
BAK has been shown to induce histopathological changes on the ocular surface. These dose-de-
pendent toxic effects were detected with very low concentrations [24]. BAK has also been im-
plicated in conjunctival allergy, dry eye disease and failure of glaucoma surgery [34–36]. These
side effects may be partially responsible for the cytotoxicity of three of the PGAs analyzed here,
and support the current trend to omit this preservative from commercial eye drop formula-
tions. In fact, some PGAs have been modified to remove BAK from their composition. As alter-
natives, new preservatives have been developed such as SofZia or Polyquad, which seem to be
less harmful to the eye [25,37]. It would be informative to compare the results of our study
with PGAs containing these new preservatives. Moreover, some commercial formulations have
been introduced on the market without preservatives, e.g. 0.03% bimatoprost and 0.005% lata-
noprost. Fewer local side effects would be expected with these products, so compliance with
treatment may be better, and the patients’ quality of life may be improved [38,39]. Interesting-
ly, the composition of one of the PGAs (bimatoprost) was changed to reduce the amount of ac-
tive component from 0.03% to 0.01%, and the concentration of BAK was increased from
0.005% to 0.02% in order to increase the effective concentration of PGA able to reach the inter-
nal tissues of the eye. The cytotoxic effects of this formulation should be stigated further.
In summary, we evaluated the cytotoxic effects of four major PGAs by using a combination
of three different methods. Our results showed a very good correlation among all three meth-
ods and point to the need for novel PGA formulations that are more sparing of the ocular sur-
face. If our results are confirmed by further studies, new clinical protocols based on the use of
lower dosages of these PGAs should be explored.
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